trivalent inactivated influenza vaccine (Vanderbilt University)

Trivalent inactivated influenza vaccine (TIV) is a seasonal vaccine designed to provide protection against three different strains of the influenza virus, typically including two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage. In clinical research conducted by the Vanderbilt-Ingram Cancer Center, TIV was evaluated in both high-dose (60 μg of hemagglutinin per strain) and standard-dose (15 μg of hemagglutinin per strain) formulations. These studies specifically targeted immunocompromised populations, such as adult and pediatric allogeneic hematopoietic stem cell transplant recipients, to determine if the higher antigen concentration could overcome reduced immune responsiveness and provide superior immunogenicity compared to standard dosing. The vaccine consists of inactivated (killed) virus particles and primarily works by inducing the production of neutralizing antibodies against the viral hemagglutinin protein.

Brand names

Fluzone High-DoseFluzone

Other names

trivalent inactivated flu vaccine-Vanderbilt-Ingram Cancer Center-influenzaTrivalent inactivated influenza vaccineHigh-Dose Trivalent Inactivated Influenza VaccineStandard Dose Trivalent Inactivated Influenza Vaccine